Get the Stockscreener App
6.39
10.36%
0.60
After Hours:
6.52
0.13
+2.03%
Solid Biosciences Inc stock is traded at $6.39, with a volume of 3.44M.
It is up +10.36% in the last 24 hours and up +37.42% over the past month.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
See More
Previous Close:
$5.79
Open:
$5.86
24h Volume:
3.44M
Relative Volume:
1.98
Market Cap:
$495.32M
Revenue:
$14.79M
Net Income/Loss:
$-102.44M
P/E Ratio:
-2.102
EPS:
-3.04
Net Cash Flow:
$-91.73M
1W Performance:
+21.48%
1M Performance:
+37.42%
6M Performance:
+95.41%
1Y Performance:
-18.08%
1-Day Range:
$5.86
$6.85
1-Week Range:
$5.2217
$6.85
52-Week Range:
$2.41
$10.37
Solid Biosciences Inc Stock (SLDB) Company Profile
Name
Solid Biosciences Inc
Sector
Industry
Phone
617-337-4680
Address
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
6.39 | 407.73M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-26-25 | Initiated | Citigroup | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-13-24 | Initiated | Wedbush | Outperform |
| Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-15-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jun-24-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Mar-28-24 | Initiated | William Blair | Outperform |
| Mar-15-24 | Initiated | Citigroup | Buy |
| Mar-14-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | Piper Sandler | Neutral |
| May-27-21 | Initiated | Jefferies | Buy |
| Mar-16-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Jan-08-21 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jul-28-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-07-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-19 | Initiated | Evercore ISI | Outperform |
| Aug-29-19 | Downgrade | Citigroup | Neutral → Sell |
| Aug-19-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-16-19 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| May-14-19 | Downgrade | Credit Suisse | Neutral → Underperform |
| May-14-19 | Downgrade | Goldman | Neutral → Sell |
| Feb-08-19 | Upgrade | Citigroup | Sell → Neutral |
| Feb-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-06-18 | Initiated | Citigroup | Sell |
| Sep-06-18 | Initiated | Credit Suisse | Neutral |
View All
Solid Biosciences Inc Stock (SLDB) Latest News
Is Solid Biosciences Inc. a good long term investmentMarket-crushing stock picks - PrintWeekIndia
Solid Biosciences Inc. Stock Analysis and ForecastConsistent high-performance stocks - Autocar Professional
What analysts say about Solid Biosciences Inc. stockFree Risk Assessment Services - jammulinksnews.com
What drives Solid Biosciences Inc. stock priceSuperior trading gains - jammulinksnews.com
What institutions are buying Solid Biosciences Inc. stock nowBreakout Level Watch - beatles.ru
Solid Biosciences’ SWOT analysis: gene therapy stock shows promise amid challenges - Investing.com Nigeria
Citi maintains Buy rating on Solid Biosciences stock amid Elevidys safety concerns - Investing.com Canada
Why Solid Biosciences Inc. stock attracts strong analyst attentionSolid Return Trade Selections - beatles.ru
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Solid Biosciences (SLDB) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail
What makes Solid Biosciences Inc. stock price move sharplyFree Investment Group - beatles.ru
Cantor Fitzgerald Remains a Buy on Solid Biosciences (SLDB) - The Globe and Mail
Solid Biosciences: SGT-003's Safety Profile Illuminates DMD Gene Therapy Path (Rating Upgrade) - Seeking Alpha
Cantor Fitzgerald reiterates Overweight rating on Solid Biosciences stock By Investing.com - Investing.com Canada
Truist Financial Reaffirms Their Buy Rating on Solid Biosciences (SLDB) - The Globe and Mail
SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Solid Biosciences Inc. (NASDAQ: SLDB) and Encourages Long-Term SLDB Investors to Contact the Firm - WV News
For Patients - Solid Biosciences
Citi Initiates Coverage on Solid Biosciences Inc. (SLDB) with ‘Buy’ Rating and $14 PT - MSN
Solid Biosciences: A Rare Gem in the Gene Therapy Race - AInvest
Solid Biosciences Inc. Initiated with 'Buy' Rating and $14 PT by Citi - AInvest
Solid Biosciences to begin testing SGT-501 in U.S. and Canada (SLDB) - Seeking Alpha
Solid Biosciences cleared to begin phase I studies of SGT-501 in US and Canada - BioWorld MedTech
Solid Biosciences Stock Pops On US, Canada Nod For Gene Therapy Trials: Retail Buzz Spikes - Stocktwits
Solid Biosciences receives FDA approval for CPVT gene therapy IND By Investing.com - Investing.com South Africa
Solid Biosciences receives FDA approval for CPVT gene therapy IND - Investing.com Australia
Solid Biosciences gets FDA IND, Health Canada CTA nod for first-in-class cardiac gene therapy CPVT - MarketScreener
Solid Biosciences Gets FDA, Health Canada Clearance to Advance Gene Therapy Trial for Cardiac Disease - MarketScreener
Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First-in-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) - The Manila Times
Breakthrough: First Gene Therapy for Fatal Heart Rhythm Disorder Advances to Clinical Trials - Stock Titan
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Solid Biosciences Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 29, 2018SLDB - ACCESS Newswire
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Solid Biosciences Expands Team: 105K RSUs Granted as New Talent Joins Genetic Medicine Pioneer - Stock Titan
Solid Biosciences Inc.(NasdaqGS: SLDB) dropped from Russell Microcap Growth Index - MarketScreener
Solid Biosciences Raises up to $50 Million in Series C Financing - Bain Capital
Is Solid Biosciences, Inc. technically bullish or bearish? - MarketsMojo
Solid Biosciences’ SWOT analysis: promising DMD gene therapy stock faces key catalysts - Investing.com
Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences - MarketBeat
SLDB: HC Wainwright & Co. Reiterates Buy Rating with $20 Target - GuruFocus
SLDB: HC Wainwright & Co. Reiterates Buy Rating with $20 Target | SLDB Stock News - GuruFocus
Solid Biosciences (SLDB) Gains Confidence Amid Safety Concerns w - GuruFocus
Solid Biosciences Inc Stock (SLDB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.59%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):